相关实验视频
Updated: May 10, 2025

04:39
Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
1.5K
甲状腺过氧化酶抗体及其在预测Graves病治疗结果中的作用
Klara Gewert1,2, Geriolda Topi1,2, Tereza Planck1,2
1Department of Clinical Sciences, Lund University, Malmö, Sweden.
Frontiers in endocrinology
|April 21, 2025
概括
在格雷夫斯病 (GD) 中,甲状腺过氧化酶抗体 (抗TPO) 不影响抗甲状腺药物 (ATD) 治疗后的复发率. 然而,抗TPO可能会减少放射性 (RI) 后的复发,并且不会增加ATD治疗后的甲状腺功能低下风险.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
背景情况:
- 格雷夫斯病 (GD) 是甲状腺功能障碍的最常见原因.
- 甲状腺过氧化酶抗体 (抗TPO) 在GD患者中很常见,但它们对治疗结果的影响尚未完全理解.
研究的目的:
- 调查GD诊断时的抗TPO阳性是否影响抗甲状腺药物 (ATD) 或放射性 (RI) 治疗后的复发率.
- 为了确定抗TPO状态是否会影响ATD治疗后患甲状腺功能低下症的风险.
主要方法:
- 在2002年至2018年期间,对712名为GD治疗的患者进行了回顾性注册表研究.
- 基于诊断时的抗TPO状态,分析复发率和甲状腺功能低下症的发展.
主要成果:
- 在抗TPO阳性和阴性患者之间,在ATD治疗后复发率没有差异.
- 抗TPO的存在与RI治疗后复发率降低有关 (13.9%vs24.6%).
- 抗TPO状态与ATD治疗后的甲状腺功能低下症发展无关;较长的ATD治疗 (>2年) 增加了甲状腺功能低下症的风险.
结论:
- 抗TPO阳性不会影响ATD后的GD复发,但可能会改善RI的长期结果.
- 抗TPO在ATD治疗后不会增加甲状腺功能低下的风险.
- 识别风险因素有助于个性化GD管理和后续战略.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
3.9K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
3.9K
Functions of Thyroid Hormones
2.3K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
2.3K
Myasthenia Gravis: Diagnostic Tests
538
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
538
Myasthenia Gravis: Overview and Treatment
958
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
958

